TargetMol

Andolast

Product Code:
 
TAR-T26628
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26628-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26628-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26628-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Andolast, also known as CR-2039, an anti-allergic agent for the treatment of bronchial asthma, chronic obstructive pulmonary disease (COPD). Andolast acts at different cellular levels to inhibit immunoglobulin E synthesis. Andolast proved to be significantly more effective than placebo in improving airflow, and in controlling asthma symptoms both during day and night.
CAS:
132640-22-3
Formula:
C15H11N9O
Molecular Weight:
333.315
Purity:
0.98
SMILES:
O=C(Nc1ccc(cc1)-c1nnn[nH]1)c1ccc(cc1)-c1nnn[nH]1

References

1. Malerba M, D Amato M, Radaeli A, Giacovelli G, Rovati L, Arshad SH, Holgate ST. Efficacy of Andolast in Mild to Moderate Asthma: A Randomized, Controlled, Double-Blind Multicenter Study (The Andast Trial). Curr Pharm Des. 2015;21(26):3835-43. PubMed PMID: 25845448. 2. Malerba M, Mennuni L, Piepoli T, Caselli G, Makovec F, Rovati LC, D' Amato M, Ferrari F. Andolast acts at different cellular levels to inhibit immunoglobulin E synthesis. Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):85-94. PubMed PMID: 19309555. 3. Nardi A, Olesen SP. BK channel modulators: a comprehensive overview. Curr Med Chem. 2008;15(11):1126-46. Review. PubMed PMID: 18473808. 4. Bay?s M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. PubMed PMID: 17805439.